Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759. doi: 10.1007/s13318-019-00577-5.

Abstract

Background and objectives: Darolutamide is a novel androgen receptor (AR) antagonist approved for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC). Accordingly, the drug-drug interaction (DDI) potential of darolutamide was investigated in both nonclinical and clinical studies.

Methods: In vitro studies were performed to determine the potential for darolutamide to be a substrate, inducer or inhibitor for cytochrome P450 (CYP) isoforms, other metabolizing enzymes and drug transporters. A phase I drug-interaction study in healthy volunteers evaluated the impact of co-administering rifampicin [CYP3A4 and P-glycoprotein (P-gp) inducer] and itraconazole [CYP3A4, P-gp and breast cancer resistance protein (BCRP) inhibitor] on the pharmacokinetics of darolutamide. Two further phase I studies assessed the impact of co-administering oral darolutamide on the pharmacokinetics of midazolam (sensitive CYP3A4 substrate) and dabigatran etexilate (P-gp substrate) and the impact on the pharmacokinetics of co-administered rosuvastatin [a substrate for BCRP, organic anion-transporting polypeptide (OATP)1B1, OATP1B3 and organic anion transporter (OAT)3].

Results: In vitro, darolutamide was predominantly metabolized via oxidative biotransformation catalyzed by CYP3A4 and was identified as a substrate for P-gp and BCRP. The enzymatic activity of nine CYP isoforms was not inhibited or slightly inhibited in vitro with darolutamide, and a rank order and mechanistic static assessment indicated that risk of clinically relevant DDIs via CYP inhibition is very low. In vitro, darolutamide exhibited no relevant induction of CYP1A2 or CYP2B6 activity. Inhibition of BCRP-, P-gp-, OAT3-, MATE1-, MATE2-K-, OATP1B1- and OATP1B3-mediated transport was observed in vitro. Phase I data showed that darolutamide exposure increased 1.75-fold with co-administered itraconazole and decreased by 72% with rifampicin. Co-administration of darolutamide with CYP3A4/P-gp substrates showed no effect or only minor effects. Rosuvastatin exposure increased 5.2-fold with darolutamide because of BCRP and probably also OATPB1/OATPB3 inhibition.

Conclusions: Darolutamide has a low potential for clinically relevant DDIs with drugs that are substrates for CYP or P-gp; increased exposure of BCRP and probably OATP substrates was the main interaction of note.

Publication types

  • Clinical Trial, Phase I

MeSH terms

  • Aged
  • Cells, Cultured
  • Cytochrome P-450 CYP3A Inducers / pharmacology
  • Cytochrome P-450 CYP3A Inhibitors / pharmacology
  • Cytochrome P-450 Enzyme System / drug effects*
  • Dabigatran / pharmacokinetics
  • Drug Interactions*
  • Enzyme Induction / drug effects
  • Female
  • Humans
  • Itraconazole / pharmacology
  • Male
  • Membrane Transport Proteins / drug effects
  • Microsomes, Liver / drug effects
  • Midazolam / pharmacokinetics
  • Middle Aged
  • Pyrazoles / blood
  • Pyrazoles / pharmacokinetics*
  • Pyrazoles / pharmacology*
  • Pyrazoles / urine
  • Rifampin / pharmacology
  • Rosuvastatin Calcium / pharmacokinetics

Substances

  • Cytochrome P-450 CYP3A Inducers
  • Cytochrome P-450 CYP3A Inhibitors
  • Membrane Transport Proteins
  • Pyrazoles
  • darolutamide
  • Itraconazole
  • Rosuvastatin Calcium
  • Cytochrome P-450 Enzyme System
  • Dabigatran
  • Midazolam
  • Rifampin